Actionnariat et activité des initiés pour Ligand Pharmaceuticals Incorporated (LGND): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $275.20 |
| Capitalisation | $5.5B |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-09-10 | Zimmermann Martine | S-Sale | 1,200 | $342K |
| 2026-09-03 | Reardon Andrew | S-Sale | 300 | $85K |
| 2026-09-03 | Reardon Andrew | S-Sale | 1,800 | $513K |
| 2026-09-03 | Reardon Andrew | S-Sale | 2,115 | $606K |
| 2026-09-03 | Reardon Andrew | S-Sale | 385 | $111K |
| 2026-09-03 | Reardon Andrew | S-Sale | 400 | $116K |
| 2026-08-12 | Espinoza Octavio | M-Exempt | 3,348 | $230K |
| 2026-08-12 | Espinoza Octavio | M-Exempt | 7,171 | $410K |
| 2026-08-12 | Espinoza Octavio | M-Exempt | 2,869 | $160K |
| 2026-08-12 | Espinoza Octavio | M-Exempt | 2,074 | $145K |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $141.0M | $201.7M | $718.4M | $71.5M | $47.6M | $19.5M | $45.0M | $23.0M | $72.3M | $174.9M |
| Placements à Court Terme | 0 | 0 | $46.2M | $998.3M | $363.6M | $321.6M | $166.9M | $147.4M | $183.9M | $558.6M |
| Créances | $18.2M | $25.6M | $55.9M | $41.7M | $59.1M | $91.6M | $35.0M | $39.3M | $42.4M | $61.0M |
| Stocks | $1.9M | $4.4M | $7.1M | $7.3M | $26.5M | $27.3M | $13.3M | $24.0M | $14.1M | $9.1M |
| Actifs Courants | $163.1M | $237.0M | $870.5M | $1.12B | $500.6M | $464.8M | $263.6M | $237.4M | $331.6M | $832.3M |
| Immobilisations Corporelles | $1.8M | $4.2M | $5.4M | $17.6M | $37.2M | $32.6M | $27.5M | $25.1M | $24.8M | $10.8M |
| Goodwill | $276.9M | $314.5M | $306.4M | $95.2M | $189.7M | $105.7M | $105.7M | $103.4M | $105.2M | $101.5M |
| Actifs Incorporels | $25.8M | $19.5M | $31.5M | $230.5M | $606.3M | $386.8M | $352.6M | $299.6M | $266.6M | $422.3M |
| Actifs Totaux | $601.6M | $671.0M | $1.26B | $1.49B | $1.36B | $1.30B | $762.7M | $787.2M | $941.8M | $1.56B |
| Dettes Fournisseurs | $2.7M | $2.3M | $4.2M | $2.4M | $3.8M | $8.4M | $5.3M | $2.4M | $5.2M | $3.2M |
| Dette à Court Terme | $212.9M | $224.5M | $26.4M | 0 | 0 | 0 | $76.7M | 0 | 0 | 0 |
| Passifs Courants | $227.1M | $238.9M | $82.2M | $17.0M | $100.1M | $41.7M | $98.8M | $16.8M | $37.1M | $37.4M |
| Dette à Long Terme | $29.6M | $18.9M | $609.9M | $639.0M | $442.3M | $320.7M | 0 | 0 | 0 | $446.2M |
| Passifs Totaux | $230.7M | $252.4M | $699.9M | $727.7M | $652.8M | $476.4M | $165.2M | $86.3M | $111.3M | $543.4M |
| Réserves | -$431.1M | -$400.9M | -$229.2M | $400.1M | $392.0M | $449.1M | $450.9M | $503.0M | $499.0M | $608.1M |
| Capitaux Propres | $370.9M | $418.6M | $560.9M | $767.2M | $709.5M | $821.2M | $597.5M | $700.9M | $830.4M | $1.02B |
| Dette Totale | $212.9M | $224.5M | $636.3M | $650.2M | $456.4M | $324.4M | $87.7M | $6.2M | $7.1M | $451.5M |
| Dette Nette | $71.9M | $22.9M | -$128.3M | -$419.7M | $45.2M | -$16.7M | -$124.1M | -$164.1M | -$249.1M | -$282.0M |
| Fonds de Roulement | -$64.1M | -$1.8M | $788.3M | $1.11B | $400.4M | $423.1M | $164.8M | $220.6M | $294.4M | $794.8M |
Santé financière
| Dette / Capitaux propres | 1.17 |
| Ratio de liquidité | 31.18 |
Rentabilité
| Marge brute | 98.58% |
| Marge opérationnelle | 34.74% |
| Marge nette | 67.88% |
Entreprises liées: ACAD · ADMA · BLTE · CRNX · DYN · MIRM · NAMS
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de LGND: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions